MedPath

Chemotherapy With or Without Immunotherapy in Treating Patients With Stage III or Stage IV Melanoma

Phase 3
Completed
Conditions
Stage IV Melanoma
Stage III Melanoma
Recurrent Melanoma
Registration Number
NCT00003647
Lead Sponsor
Vical
Brief Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Injecting allovectin-7 into a person's melanoma cells may make the body build an immune response that will kill tumor cells.

PURPOSE: Randomized phase III trial to compare the effectiveness of dacarbazine with or without immunotherapy in treating patients who have stage III or stage IV melanoma.

Detailed Description

OBJECTIVES: I. Demonstrate either an improvement in the median time to disease progression by at least 2 months with no decrease in the rate of objective clinical response OR an improvement by at least 15% in the rate of objective clinical response with no decrease in the median time to disease progression in patients with stage III or IV melanoma receiving dacarbazine with Allovectin-7 when compared with patients receiving dacarbazine alone.

II. Determine the benefits, risks, and side effects of these regimens in this patient population.

PROTOCOL OUTLINE: This is a randomized, multicenter study. Patients are stratified according to sex, age, and spread of disease (cutaneous or nodal vs visceral disease). Patients are randomized to one of two treatment arms.

Arm I: Patients receive dacarbazine IV over 1 hour on day 0. Arm II: Patients receive treatment as in arm I. Patients also receive Allovectin-7 intratumorally on days 3 and 10.

Patients with stable or responding disease may receive additional courses every 28 days.

Patients are followed every 4 months.

PROJECTED ACCRUAL:

A total of 280 patients (140 in each arm) will be accrued for this study.

Recruitment & Eligibility

Status
COMPLETED
Sex
Not specified
Target Recruitment
Not specified
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (44)

Oncology and Hematology Associates

🇺🇸

Westwood, Kansas, United States

Comprehensive Blood and Cancer Center

🇺🇸

Bakersfield, California, United States

Mayo Clinic Cancer Center

🇺🇸

Rochester, Minnesota, United States

Kaiser Permanente-Southern California Permanente Medical Group

🇺🇸

San Diego, California, United States

Franklin Square Hospital Center

🇺🇸

Baltimore, Maryland, United States

Virginia Piper Cancer Institute

🇺🇸

Minneapolis, Minnesota, United States

Arena Oncology Associates

🇺🇸

Great Neck, New York, United States

Mid Dakota Clinic, P.C.

🇺🇸

Bismarck, North Dakota, United States

Providence Hospital Cancer Center

🇺🇸

Southfield, Michigan, United States

Mid-Ohio Oncology/Hematology, Inc.

🇺🇸

Columbus, Ohio, United States

University of Pennsylvania Cancer Center

🇺🇸

Philadelphia, Pennsylvania, United States

North Memorial Health Care

🇺🇸

Robbinsdale, Minnesota, United States

Huntsman Cancer Institute

🇺🇸

Salt Lake City, Utah, United States

Bergan Mercy Medical Center

🇺🇸

Omaha, Nebraska, United States

Medical College of Wisconsin

🇺🇸

Milwaukee, Wisconsin, United States

Robert H. Lurie Comprehensive Cancer Center, Northwestern University

🇺🇸

Chicago, Illinois, United States

Lutheran General Hospital

🇺🇸

Park Ridge, Illinois, United States

Scripps Memorial Hospitals-Stevens Cancer Center - Encinitas

🇺🇸

Encinitas, California, United States

Yale Comprehensive Cancer Center

🇺🇸

New Haven, Connecticut, United States

H. Lee Moffitt Cancer Center and Research Institute

🇺🇸

Tampa, Florida, United States

Georgia Cancer Specialists, P.C.

🇺🇸

East Point, Georgia, United States

Georgia Cancer Specialists

🇺🇸

Decatur, Georgia, United States

Cancer Care Center

🇺🇸

New Albany, Indiana, United States

Cancer Centers of the Carolinas

🇺🇸

Greenville, South Carolina, United States

Washington Cancer Institute

🇺🇸

Washington, District of Columbia, United States

University of Arkansas for Medical Sciences

🇺🇸

Little Rock, Arkansas, United States

Mount Sinai Comprehensive Cancer Center

🇺🇸

Miami Beach, Florida, United States

Cancer Care Center for Southern Indiana

🇺🇸

Bloomington, Indiana, United States

St. Francis Medical Center

🇺🇸

Honolulu, Hawaii, United States

Lucille Parker Markey Cancer Center, University of Kentucky

🇺🇸

Lexington, Kentucky, United States

Louisiana State University School of Medicine

🇺🇸

New Orleans, Louisiana, United States

St. Louis University Health Sciences Center

🇺🇸

Saint Louis, Missouri, United States

Billings Interhospital Oncology Project

🇺🇸

Billings, Montana, United States

Missouri Baptist Cancer Center

🇺🇸

Saint Louis, Missouri, United States

Norris Cotton Cancer Center

🇺🇸

Lebanon, New Hampshire, United States

Park Nicollet Clinic

🇺🇸

St. Louis Park, Minnesota, United States

HemOnCare, P.C.

🇺🇸

Brooklyn, New York, United States

Mount Sinai School of Medicine

🇺🇸

New York, New York, United States

Beth Israel Medical Center

🇺🇸

New York, New York, United States

Comprehensive Cancer Center at Wake Forest University

🇺🇸

Winston-Salem, North Carolina, United States

Toledo Clinic, Inc.

🇺🇸

Toledo, Ohio, United States

Seattle Cancer Care Alliance

🇺🇸

Seattle, Washington, United States

Danville Hematology and Oncology, Inc.

🇺🇸

Danville, Virginia, United States

Cancer Treatment Centers of America in Hampton Roads

🇺🇸

Portsmouth, Virginia, United States

© Copyright 2025. All Rights Reserved by MedPath